^
Association details:
| Biomarker: | BRAF V600K |
|---|---|
| Cancer: | Melanoma |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: New recurrence-free survival results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial at three-year median follow-up.
Published date:
05/13/2020
Excerpt:
At 3.05-yr median follow-up, pembrolizumab (190 RFS events) compared with placebo (283 RFS events) prolonged RFS, in the overall population and in the PD-L1 positive tumor subgroup (see Table). RFS was consistently prolonged across subgroups, in particular according to AJCC-7 staging, BRAF-V600 E/K mutation status.
DOI:
10.1200/JCO.2020.38.15_suppl.10000
Trial ID:
Source:
Title:
Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma
Excerpt:
...Male/female participants who are at least 18 years of age on the day of signing informed consent with histologically confirmed diagnosis of metastatic melanoma with BRAF V600E/K mutation will be enrolled in this study....
Trial ID:
Source:
Title:
Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer
Excerpt:
...If the melanoma expresses a BRAF mutation of V600E, V600K, or V600R patient must have received and progressed through a BRAF inhibitor or have failed that therapy due to toxicity....
Trial ID:
Less C2 evidence
Source:
Title:
Prescription Patterns, Recurrence, and Toxicity Rates of Adjuvant Treatment for Stage III/IV Melanoma-A Real World Single-Center Analysis
Published date:
03/10/2022
Excerpt:
Of 40 (36.7%) patients with BRAF V600E/K melanoma, pembrolizumab was prescribed to 18 (45.0%), nivolumab to 16 (40.0%)...Thirty-eight percent of the patients treated with pembrolizumab and 40.0% of those treated with nivolumab relapsed.
DOI:
10.3390/biology11030422
Source:
Title:
Distinct molecular profiles and immunotherapy treatment outcomes of V600E and V600K BRAF-mutant melanoma
Excerpt:
In patients treated with anti-PD-1, V600K (n=19) had superior outcomes than V600E (n=84), including response rate (53% vs 29%, p=0.059), PFS (median 19 vs 2.7 months, p=0.049) and overall survival (20.4 vs 11.7 months, p=0.081)….An independent cohort of V600E/K BRAF-mutant metastatic melanoma patients treated with anti-PD-1 immunotherapy (pembrolizumab or nivolumab)...
DOI:
10.1158/1078-0432.CCR-18-1680
